186 related articles for article (PubMed ID: 9792357)
1. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
Forsythe SS
AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of delaying or preventing AIDS in persons with HIV.
Pinkerton SD; Holtgrave DR
Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. A French lesson. French experience shows full funding of treatment advances saves money.
Alcorn K
J Int Assoc Physicians AIDS Care; 1997 Apr; 3(4):49. PubMed ID: 11364203
[TBL] [Abstract][Full Text] [Related]
6. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
8. Evolution of socioeconomic impact assessments of HIV/AIDS.
Forsythe S; Rau B
AIDS; 1998; 12 Suppl 2():S47-55. PubMed ID: 9792361
[TBL] [Abstract][Full Text] [Related]
9. The end of AIDS?
Leland J
Newsweek; 1996 Dec; 128(23):64-8, 71, 73. PubMed ID: 10162943
[No Abstract] [Full Text] [Related]
10. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
11. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy and resistance to antiretroviral drugs.
Lange JM; van Leeuwen R
Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
[TBL] [Abstract][Full Text] [Related]
13. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Krentz HB; Auld MC; Gill MJ;
CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
[TBL] [Abstract][Full Text] [Related]
14. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
15. Costs associated with combination antiretroviral therapy in HIV-infected patients.
Yazdanpanah Y
J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
17. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
18. AIDS in the Third World: how to stop the HIV infection?
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
[TBL] [Abstract][Full Text] [Related]
19. [New therapy for AIDS: a double-edged sword].
Foreman M
Sidahora; 1996; ():38-9. PubMed ID: 11364382
[TBL] [Abstract][Full Text] [Related]
20. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
